All news (page 57)

• 

  2 March 2026

  Takeda's Rusfertide Receives FDA Priority Review

  Rusfertide shows promise in controlling hematocrit and reducing symptoms in polycythemia vera, with FDA review based on positive Phase 3 and long-term study data.
• 

  2 March 2026

  Equinor's Rapid Development Plan for Snorre Oil Discovery

  New oil discovery in Snorre area to be quickly developed using existing infrastructure, reducing costs and environmental impact, while supporting European energy security.
• 

  2 March 2026

  thyssenkrupp Uhde to Study Biomass-to-Methanol Integration for Nova Sustainable Fuels in Canada

  The study will assess the integration of gasification and methanol synthesis to produce 450,000 metric tons of bio-methanol annually, aiding decarbonization in transportation and shipping.
• 

  2 March 2026

  Galp 4Q & FY25 Financial Results

  Strong 2025 performance with €2.2bn cash generation, 4% DPS increase, and €250m buyback. Key growth in Brazil, Namibia, and Sines. Net debt at €1.3bn, FCF at €81m.
• 

  2 March 2026

  WuXi Biologics in S&P Global Sustainability Yearbook for Fourth Year

  Recognized for top sustainability performance, achieving a Top 1% S&P Global CSA Score, and earning multiple ESG accolades across various indices and initiatives.
• 

  2 March 2026

  Mitsui Chemicals Unveils AI for Efficient R&D Literature Reviews

  An AI agent reduces literature review time by 80%, automating compound identification and data extraction from scientific texts, enhancing R&D efficiency.

• 

  1 March 2026

  Dangote Cement signs $1bn deal with Sinoma for 12 African cement projects

  Deal backs new plants, expansions and upgrades across Africa to raise capacity toward an 80 MTPA 2030 target, secure gas supply, improve efficiency, cut emissions and create jobs.
• 

  1 March 2026

  Genentech's Fenebrutinib Shows Promise as BTK Inhibitor for MS in Phase III Study

  Fenebrutinib reduced relapses by 51% in RMS, consistent with prior studies. Data will be submitted to regulators. Safety profile comparable to teriflunomide; further analysis on fatalities ongoing.
• 

  28 February 2026

  Merck's KEYTRUDA and WELIREG Combo Reduces RCC Recurrence Risk by 28%

  Phase 3 trial shows KEYTRUDA and WELIREG improve disease-free survival in RCC. FDA accepts priority review for adjuvant treatment. Safety profile consistent with previous studies.
• 

  28 February 2026

  Merck and Eisai: WELIREG and LENVIMA Reduce Disease Progression Risk by 30% in Advanced RCC Trial

  Phase 3 trial shows WELIREG plus LENVIMA improves progression-free survival in advanced RCC, with FDA reviewing new drug applications.
• 

  27 February 2026

  CATL and BMW MOU on Battery Passport and Decarbonization

  MOU to run pilots for cross-border Battery Passport data exchange, carbon accounting and Catena‑X standards, aligning tech, policies and EU compliance to boost low‑carbon competitiveness.
• 

  27 February 2026

  PETRONAS Reports Lower Profit Amid Market Challenges, Focuses on Long-Term Value

  Revenue and profit decreased due to lower prices and sales. PETRONAS prioritizes resilience and strategic growth amid ongoing market volatility and geopolitical challenges.
• 

  27 February 2026

  ZILS Investments Surpass €20 Billion, Boosting Regional Growth

  ZILS attracts major investments in energy, industry, and tech, enhancing Sines' role as a key production and export hub, creating jobs and boosting economic competitiveness.
• 

  27 February 2026

  FDA Approves Novo Nordisk's Sogroya for New Pediatric Uses

  Sogroya, a once-weekly growth hormone, is now approved for children with ISS, SGA, or NS, offering an alternative to daily injections and expanding treatment options.
• 

  27 February 2026

  Merck's KEYTRUDA and Padcev Cut Event-Free Survival Risk by 47% and Mortality by 35% in Cisplatin-Eligible Bladder Cancer Patients

  KEYTRUDA plus Padcev improves survival and reduces recurrence in muscle-invasive bladder cancer, showing potential as a new standard for cisplatin-eligible patients.
• 

  27 February 2026

  Merck's KEYTRUDA Plus Paclitaxel Boosts Survival in Platinum-Resistant Ovarian Cancer

  KEYTRUDA plus paclitaxel improves overall survival in platinum-resistant ovarian cancer, regardless of PD-L1 status, as shown in the KEYNOTE-B96 trial.
• 

  27 February 2026

  aicep Global Parques Enhances Angola Business Park Cooperation

  From February 23-26, a visit to Angola focused on sharing best practices, fostering synergies, and exploring collaboration in industry, logistics, and sustainable development.
• 

  27 February 2026

  Lilly's Olumiant Gains CHMP Nod for Adolescent Alopecia Areata in EU

  CHMP backs Olumiant for severe alopecia areata in adolescents, based on Phase 3 study showing 42% achieved 80% scalp hair coverage at 36 weeks. Awaiting European Commission decision.
• 

  27 February 2026

  KazMunayGas 2025 Trading Update

  Hydrocarbon reserves stable; oil and gas production up. Oil transport steady; refining and polypropylene output increased.
• 

  27 February 2026

  CABB Group Sells Jayhawk Fine Chemicals to Anupam Rasayan

  CABB shifts focus to Pharma and Life Science, selling Jayhawk for $150M. Anupam Rasayan aims to expand its US presence and performance materials business.
• 

  27 February 2026

  Air Liquide and Holcim Partner to Decarbonize Belgian Cement Production

  The agreement aims to capture 1.1 million tons of CO₂ annually at Holcim's Obourg plant, supporting EU's 2050 net zero target through advanced carbon capture and storage technology.
• 

  27 February 2026

  Ercros Reports EUR 8M EBITDA, EUR 54M Loss

  Weak demand, high energy costs, and competition impact results. Cost reduction plan on track. Financial debt reduced. Takeover bid rejected. Demand recovery expected in late 2026.
• 

  27 February 2026

  Neste Board Nominee Withdraws from 2026 AGM Election

  Simo Sääskilahti withdraws from Board election. The Board will have eight members. Remaining candidates are proposed for election.
• 

  27 February 2026

  BASF Advances "Winning Ways" Strategy Milestones

  BASF boosts free cash flow, starts Zhanjiang plants, and cuts costs. 2025 EBITDA drops to €6.6B; 2026 outlook: €6.2-7.0B EBITDA, €1.5-2.3B free cash flow.
• 

  26 February 2026

  GSK's Bepirovirsen Under Review in Japan for Chronic Hepatitis B Treatment

  Japan reviews bepirovirsen for chronic hepatitis B. Phase III trials show higher functional cure rates and acceptable safety. SENKU designation granted for expedited review.
• 

  26 February 2026

  GSK's Linerixibat Gets Priority Review in China for PBC-Related Itch

  Linerixibat shows significant improvement in cholestatic pruritus in PBC patients, based on GLISTEN phase III trial data. Regulatory reviews ongoing in US, EU, UK, and Canada.
• 

  26 February 2026

  thyssenkrupp Automotive Body Solutions Joins IPAI for Smart Manufacturing Innovation

  The company joins IPAI to integrate AI in manufacturing, enhancing robotics and expanding globally, with a focus on intelligent production and quality monitoring.
• 

  26 February 2026

  Indaver to Acquire Medway Energy Centre from Low Carbon

  Indaver plans to expand waste treatment in SE England, generating low-carbon electricity. The project aligns with their UK strategy and complements Low Carbon's development efforts.
• 

  26 February 2026

  Grupa Azoty Introduces New Sulphur-Containing Fertilizer

  The new product strengthens the fertilizer segment, supporting stable growth and competition in Europe while enhancing food security in Poland and the region.
• 

  26 February 2026

  MOL Accuses JANAF of Legal Violations Over Russian Oil Transit

  MOL demands JANAF allow unsanctioned Russian oil via sea, citing EU/US rules. Non-compliance may lead to legal action and claims for damages.